Johnson & Johnson MedTech, the medical technology arm of Johnson & Johnson (J&J) on Thursday said the U.S. Food and Drug Administration (FDA) has approved an expanded indication for its TRUFILL n-BCA Liquid Embolic System. The device is now cleared for embolization of the middle meningeal artery (MMA) as an adjunct to surgery in the treatment of symptomatic subacute and chronic subdural hematoma (cSDH).
The approval is supported by the MEMBRANE study, which evaluated the safety and effectiveness of MMA embolization in patients with cSDH. The study found that TRUFILL n-BCA was more effective than standard of care for MMA embolization in treating symptomatic cSDH, while demonstrating a favorable safety profile.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.